Hemogenyx Pharmaceuticals PLC (LSE: HEMO, OTC: HOPHF) announced a “major milestone” by launching its first trial site and beginning patient recruitment for the clinical trial of its flagship drug, which
Hemogenyx Pharma Plc (HEMO.L) Hemo-CAR-T partnership with WuXi ATU
Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programme
Hemogenyx Pharma Plc (HEMO.L) HEMO-CAR-T pre-IND Meeting Request
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases.